Skip to main content

Table 1 Monoclonal antibodies

From: How mathematical modeling could contribute to the quantification of metastatic tumor burden under therapy: insights in immunotherapeutic treatment of non-small cell lung cancer

Antibody Type Year of approval (FDA) Molar Mass Mi [kDa] Approved Dosages Half-life \(t^{1/2}_{i}\) [d] Sources
Atezolizumab humanized 2016 145 1200mg q3w 27 [70, 71]
Avelumab human 2017 143 800mg q2w 6.1 [72, 73]
Durvalumab human 2017 146 10mg/kg q2w 18 [74, 75]
Nivolumab human 2014 146 240mg q2w or 480mg q4w 26.7 [76, 77]
Pembrolizumab humanized 2014 146 200mg q3w or 400mg q6w 22 [78, 79]
Cemiplimab human 2018 144 350mg q3w 19.4 [80, 81]
  1. Currently approved monoclonal antibodies used as immunotherapeutics targeting the PD-1 pathway. The application cycle length l used in the model is determined from the dosage, e.g. the expression “q3w” reads “every three weeks”, thus l=3